These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 4082286)

  • 1. Vindesine in plasma cell tumors.
    Salvagno L; Paccagnella A; Chiarion Sileni V; De Besi P; Frizzarin M; Casara D; Fiorentino MV
    Tumori; 1985 Dec; 71(6):533-6. PubMed ID: 4082286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vindesine in refractory multiple myeloma.
    van der Lelie H; Monasch E; Pegels HG; von dem Borne AE
    Cancer; 1986 Jan; 57(2):226-9. PubMed ID: 3942957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptichemio in pretreated patients with plasmacell neoplasms.
    Paccagnella A; Salvagno L; Chiarion-Sileni V; Bolzonella S; De Besi P; Frizzarin M; Pappagallo GL; Fosser VP; Fornasiero A; Segati R
    Eur J Cancer Clin Oncol; 1986 Sep; 22(9):1053-8. PubMed ID: 3780812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II evaluation of vindesine in mycosis fungoides, extraosseous plasmacytoma and other hematologic malignancies.
    Ferrazzi E; Pappagallo GL; Segati R; Vinante O; Galligioni E; Zagonel V; Salvagno L; Fiorentino MV
    Tumori; 1982 Aug; 68(4):321-4. PubMed ID: 7147357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophosphamide, doxorubicin, prednisone and vindesine combination chemotherapy in melphalan-resistant multiple myeloma.
    Van Dobbenburgh OA; Houwen B; Piersma H; Marrink J; Ockhuizen T; Halie MR; Nieweg HO
    Neth J Med; 1984; 27(2):25-30. PubMed ID: 6709108
    [No Abstract]   [Full Text] [Related]  

  • 6. OPP-EBV-CAD regimen as salvage treatment in advanced refractory or resistant multiple myeloma.
    Colombi M; Guffanti A; Alietti A; Latargia ML; Vener C; Maiolo AT; Baldini L
    Leuk Lymphoma; 2000 Dec; 40(1-2):87-94. PubMed ID: 11426632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vincristine-cyclophosphamide, the classical two-drug regimen for small-cell lung cancer, evaluated in a randomized study with vindesine.
    Niiranen A; Holsti LR; Salmo M; Holsti P; Mattson K
    Am J Clin Oncol; 1987 Dec; 10(6):507-11. PubMed ID: 2825508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prednisone pulse therapy for refractory myeloma.
    Alexanian R; Yap BS; Bodey GP
    Blood; 1983 Sep; 62(3):572-7. PubMed ID: 6882916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs.
    Sørensen JB; Hansen HH; Dombernowsky P; Bork E; Malmberg R; Aabo K; Bødker B; Hansen M
    J Clin Oncol; 1987 Aug; 5(8):1169-77. PubMed ID: 3040918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of extramedullary gastric plasmacytoma with the combination of bortezomib and dexamethasone: first reported case.
    Katodritou E; Kartsios C; Gastari V; Verrou E; Mihou D; Banti A; Lazaraki G; Lazaridou A; Kaloutsi V; Zervas K
    Leuk Res; 2008 Feb; 32(2):339-41. PubMed ID: 17560647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vindesine for recurrent and metastatic cancer of the uterine cervix: a phase II study.
    Rhomberg WU
    Cancer Treat Rep; 1986 Dec; 70(12):1455-7. PubMed ID: 3791258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin plus vindesine in advanced breast cancer: a phase II trial of the EORTC Breast Cancer Cooperative Group.
    Paridaens R; Clarysse A; Rozencweig M; Rotmensz N; Heuson JC
    Eur J Cancer Clin Oncol; 1985 May; 21(5):595-9. PubMed ID: 4040025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). The Japan Vinorelbine Lung Cancer Cooperative Study Group.
    Furuse K; Fukuoka M; Kuba M; Yamori S; Nakai Y; Negoro S; Katagami N; Takada Y; Kinuwaki E; Kawahara M; Kubota K; Sakuma A; Niitani H
    Ann Oncol; 1996 Oct; 7(8):815-20. PubMed ID: 8922195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of continuous vindesine administration of advanced breast cancer resistant to chemotherapy including adriamycin.
    Adachi I; Watanabe T; Suzuki M; Tsuchihashi T; Yin DF; Yamaguchi K; Abe K
    Jpn J Clin Oncol; 1991 Jun; 21(3):180-7. PubMed ID: 1942549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical analysis of multiple myeloma with extramedullary plasmacytomas].
    Li X; Sun WJ; Chen SL; Zhong YP; An N; Hu Y; Zhang JJ; Liu XH
    Zhonghua Yi Xue Za Zhi; 2012 Mar; 92(12):838-41. PubMed ID: 22781459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Plasmacytoma with multiple hypervascular lesions revealed by angiography in a patient with multiple myeloma].
    Handa H; Irisawa H; Komatsumoto S; Matsushima T; Tsukamoto N; Nojima Y; Murakami H
    Rinsho Ketsueki; 2006 Jun; 47(6):521-5. PubMed ID: 16862980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer].
    Le Chevalier T; Brisgand D; Pujol JL; Douillard JY; Monnier A; Rivière A; Chomy P; Le Groumellec A; Ruffie P; Gottfried M; Gaspard MH; Chevreau C; Alberola V; Cigolari S; Besson F; Martinez A; Besenval M; Berthaud P; Tursz T
    Bull Cancer; 1996 May; 83(5):385-94. PubMed ID: 8680091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Five-day continuous infusion of vindesine in the treatment of non-small cell lung cancer--clinical pharmacokinetics of vindesine].
    Saito Y; Mori K; Tominaga K; Yokoi K; Miyazawa N
    Gan To Kagaku Ryoho; 1991 Sep; 18(12):2129-32. PubMed ID: 1653559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.